IMPC-Industry Liaison WorkshopWelcome & Intro

Tom Weaver

Director, Mary Lyon Centre,

MRC Harwell

Wellcome Trust

London, 7th April 2011

IMPC-Industry Liaison Workshop

Agenda & Discussion Sessions

IMPC Overview – Mark Moore, IMPC/NIH

Perspectives on Engagement Models – Before Lunch (12:45)1. Large Pharma – Steve Harrison, GSK2. Preferred Suppliers – Paul Rounding, Taconic

Perspectives on Engagement Models – After Lunch (1:30)3. IMPC as Service Provider/CRO, Yann Herrault (ICS)4. Database Support or Tool Developers, Abel Ureta-Vidal, Eagle

Genomics

Break for Tea/Coffee @ 3:30

Review Main Points & Wrap Up by 4-4:30

IMPC-Industry Liaison Workshop

IMPC & Industry - Context

National funding strategies demand collaboration Knowledge transfer and innovation (science, technology, applications to

create new markets and jobs) Basic research & focus on “Translation”

Vendors/Suppliers/Biotech provide academic researchers with... Essential tools and platforms for creating and working with mouse

models Their support helps drive innovation

Pharma Biotech exploit mouse models for drug development Thirty-four of the top 100 drugs by sales volume (>$44B) in the US were

enabled by the use of a mouse models. There is a high degree of correlation between mode of action of drugs in

humans and the phenotypes of their corresponding targets in mice.

IMPC-Industry Liaison Workshop

Osteoporosis Drug “Prolia®“(Denosumab)

The discovery program began in an Amgen lab when researchers observed that one of the knockout mice it had developed during

gene disabling research work had grown huge.

"We noticed, hey that's a really big mouse," Amgen CEO Kevin Sharer recently told the Wall Street Journal.

"It's really got big bones."

2% Stock Rise

$2B Value!

IMPC-Industry Liaison Workshop

IMPC & Industry - Challenge

IMPC NEEDS TO:

Ensure that the output of the IMPC truly does benefit biopharmaceutical research and development programs.

Take into account the expert views, experiences and expectations of industry researchers working with mouse models or providing products, pre-clinical services, or enabling technology platforms.

IMPC-Industry Liaison Workshop

IMPC Governance & Management11 Academic, Government Institutes

To Date, No Industry Partners

Engagement Essential

Strategy Needed

Set up Working Group

Steering Committee & Secretariat MRC Harwell (Steve Brown, current Chair;

Tom Weaver) Secretariat (Mark Moore, Executive Director;

Jorg Rossbacher) MRC (Nathan Richardson, Clare Newland) NIH (Jane Peterson, Eric Green, Jim Battey,

Colin Fletcher, Martin Guyer) Sanger Institute (Alan Bradley, Karen

Kennedy) Wellcome Trust (Michael Dunn, Clare

McVicker) Infrafrontier (Martin Hrabe de Angelis) Helmholtz Zentrum Munich (GMC) (Martin

Hrabe de Angelis) Toronto Centre for Phenogenomics (TCP)

(Colin McKerlie) Institute Clinique de la Souris (ICS) (Yann

Herault) Australian Phenomics Network (Adrienne

McKenzie) European Commission (Jacques Remacle,

observer)

IMPC-Industry Liaison Workshop

IMPC Industry Working Group

Allan Bradley, WTSI, Cambridge UK, abradley@sanger.ac.uk

Martin Hrabe-deAngelis, GMC, Munich Germany, hrabe@helmholtz-muenchen.de

Colin McKerlie, TCP, Toronto Canada, colin.mckerlie@phenogenomics.ca

Mark Moore, NIH/IMPC, San Francisco USA, mwmoore880@comcast.net

Tom Weaver (Chair), MRC Harwell, Oxford UK, t.weaver@har.mrc.ac.uk

IMPC-Industry Liaison Workshop

IMPC Industry Working Group

Remit: The working group is tasked to developing a strategy for liaising

with Industry and making recommendations for consideration by the IMPC steering committee.

Goals: How the IMPC can best serve the needs of the biopharmaceutical

industry.

Communicate with industry about our program.

Explore how industry can participate in the IMPC.

Develop and implement an engagement plan.

IMPC-Industry Liaison Workshop

Planned Activities

Draft Engagement Plan Consider Different Models Begin Discussing with Industry

Contact List (>100 so far)

Workshop (London, April 7th)

Sign-off By Steering Committee

Launch @ Bio2011 (Washington DC, July 2011)

IMPC-Industry Liaison Workshop

Goals of London Workshop

Value Add: How can the IMPC best serve the needs of the biopharmaceutical industry and its product and service providers? What can this academic consortium be providing to industry that they can’t or are not willing to do themselves?

Partnering: Gauge what interest BioPharma, Contract Research Organizations, and platform vendors have for participating in the IMPC, and propose one or several models for developing IMPC - Industry partnerships.

Contribution: What can industry offer the IMPC? Consider opportunities for industry to contribute either funds or in kind resources such as services, reagents, information, or technology to advance the program.

Communication: What are the best ways to communicate with industry about IMPC so that they are aware of this important research program and access to data, technology, analysis tools, and mouse models.

IMPC-Industry Liaison Workshop

Outcome of Our Meeting

Consensus On:

IMPC Value Proposition To Industry

Realistic Engagement Model for Industrial Involvement

Identify Barriers To Making This Happen

How To Communicate & Attract Champions

Leading To Industry Engagement Strategy & Action Plan

IMPC-Industry Liaison Workshop

Thank You For Participating!